MINNEAPOLIS--(BUSINESS WIRE)--Anulex Technologies, Inc., a privately held medical device manufacturer focusing on spinal disc Preservation & Anular RepairTM products, announced the close of its fourth round of private equity financing, totaling approximately $10.2 million. Investors leading the round include Affinity Capital, Delphi Ventures, MB Venture Partners, New Enterprise Associates, SightLine Partners and Split Rock Partners.
Commenting on the financing, Rich Lunsford, Anulex’s President and Chief Executive Officer, said, “This financing will give us the ability to complete the enrollment and follow-up phases of our ground-breaking Xclose post market clinical study with the goal of providing further evidence to support the benefits of preservation and repair of the anulus. It will also provide additional investment for our U.S. commercialization efforts and further support the company’s innovative research and development strategy.”
In addition, two new Vice Presidents have recently been appointed to Anulex’s Senior Management Team. David M. Noel was appointed Vice President of Finance and Chief Financial Officer in February 2009. Prior to joining Anulex, Mr. Noel served in a similar role at Lifecore Biomedical, Inc. a privately held company which designed and marketed dental implants and manufactures hyaluronan for use in various surgical markets. Matt Meyer was appointed Vice President of Sales and Marketing, in March 2009. Previously, Mr. Meyer served as Vice President of Marketing for KFx Medical, a privately held sports medicine device company. Prior to this position, Mr. Meyer served for over ten years, in a variety of senior marketing and sales positions, with Medtronic Spinal and Biologics.
“We are delighted by the additions of David and Matt to the Anulex team. Both bring excellent experience in the medical device field as we continue to expand our market leadership position in anular repair”, said Mr. Lunsford.
Anulex Technologies, Inc. is a privately held company dedicated to the development and commercialization of unique and proprietary soft tissue repair products with primary interests in treatments for the soft tissues of the spine. Back pain afflicts four out of every five individuals at some point during their life, and it is a major cause of disability. To date, Anulex has raised approximately $48.4 million through four rounds of financing to support these efforts. More information on the Company can be found at www.anulex.com.
Xclose, Anulex, and Preservation & Anular Repair are trademarks of Anulex Technologies, Inc.
Anulex Technologies, Inc.
Julie Osterberg, 952-224-4043